NK520

· Base Therapeutics (Shanghai) Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NK520, covering 2024-08-07 to 2024-08-07. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia [EARLY_Phase 1]